{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-21-000017","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.908954+00:00","generated_at":"2026-06-28T09:52:52.673224+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroPace Q3 revenue drops 19% to $10.3M; net loss widens to $8.1M","bullets":["Q3 total revenue $10.3M down 19% YoY; initial implant revenue $7.8M down 15%.","Net loss $8.1M vs $4.1M loss in prior year; gross margin 72.6% vs 75.0%.","Updated FY2021 guidance: total revenue $44-44.5M (7-8% growth), initial implant $33-33.5M.","Received IDE approval for clinical study to expand indication to primary generalized epilepsy.","Added Lisa Andrade to Board; submitted PMA supplement for longer battery life claim (nearly 11 yrs)."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-21-000017","json":"https://secwatch.observer/filing/0001528287-21-000017.json","markdown":"https://secwatch.observer/filing/0001528287-21-000017.md","text":"https://secwatch.observer/filing/0001528287-21-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828721000017/0001528287-21-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828721000017/npce-20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:52:52.673224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}